- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07583758
Clinical Trial on the Methodology of Hysterosalpingography: a Comparative Study (MethodHSG)
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Istanbul, Türkei (türkiye), 34214
- Istanbul Medipol University, Medipol Mega University Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Female patients with infertility
Exclusion Criteria:
- Male patients
- Patients who are diagnosed with menopause
- Patients who do not want to proceed with HSG for diagnosis purposes
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Versorgungsforschung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Group 1: Metal Cannula
Applied to 158 infertile women.
While the patient was made to cough forcefully, a tenaculum was gently inserted into the cervix.
A Rubin cannula, de-aired and filled with radiopaque, was placed in the cervical canal.
The speculum was removed.
Traction was applied to the tenaculum to bring the uterus into a straight position, and while radiopaque material was injected under fluoroscopy, the cavity, tubal corneum, isthmus, ampulla, and degree of spillage into the abdomen were visualized.
|
Different techniques of hysterosalpingography (HSG) were applied for 3 groups in parallel.
|
|
Aktiver Komparator: Group 2: Active Method Balloon Catheter
Applied to 50 infertile women.
In this case, a balloon catheter was placed from the cervix into the uterine cavity.
A 2cc balloon was inflated.
The uterus was brought to a straight position by applying traction to the balloon catheter, and the cavity, tubal corneum, isthmus, ampulla, and degree of spillage into the abdomen were visualized while radiopaque material was injected under fluoroscopy guidance.
The uterine isthmus was visualized while the balloon was being deflated and withdrawn.
|
Different techniques of hysterosalpingography (HSG) were applied for 3 groups in parallel.
|
|
Aktiver Komparator: Group 3: Passive Method Balloon Catheter
Applied to 43 infertile women.
In this case, a balloon catheter was placed from the cervix into the uterine cavity.
A 2cc balloon was inflated.
While the balloon catheter was in the cavity, the tubal corneum, isthmus, ampulla, and degree of spillage into the abdomen were visualized by first injecting radiopaque material under fluoroscopy guidance.
Then, the cavity was visualized while the balloon catheter was being deflated and withdrawn, and the uterine isthmus was visualized.
This procedure was called the passive method balloon catheter method.
|
Different techniques of hysterosalpingography (HSG) were applied for 3 groups in parallel.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Patient Satisfaction
Zeitfenster: Day 1
|
Patients' visual analogue scores (VAS) immediately after the procedure and 30 minutes post-procedure are recorded, respectively. The pain is assessed by the principal investigator. The visual analog scale for pain is a straight line with one end meaning no pain and the other end meaning the worst pain imaginable. The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10 cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be'). |
Day 1
|
|
Clinician's Interpretation
Zeitfenster: Day 1
|
The interpretation is classified as "clearly evaluated", "partially evaluated" and as "could not be evaluated" by the clinician.
|
Day 1
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Gulseren Polat, M.D., Medipol University
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Pellerito JS, McCarthy SM, Doyle MB, Glickman MG, DeCherney AH. Diagnosis of uterine anomalies: relative accuracy of MR imaging, endovaginal sonography, and hysterosalpingography. Radiology. 1992 Jun;183(3):795-800. doi: 10.1148/radiology.183.3.1584936.
- Preutthipan S, Linasmita V. A prospective comparative study between hysterosalpingography and hysteroscopy in the detection of intrauterine pathology in patients with infertility. J Obstet Gynaecol Res. 2003 Feb;29(1):33-7. doi: 10.1046/j.1341-8076.2003.00068.x.
- Chalazonitis A, Tzovara I, Laspas F, Porfyridis P, Ptohis N, Tsimitselis G. Hysterosalpingography: technique and applications. Curr Probl Diagn Radiol. 2009 Sep-Oct;38(5):199-205. doi: 10.1067/j.cpradiol.2008.02.003.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- E-10840098-772.02-275
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Data is available upon reasonable request from the principal investigator, Dr. Gulseren Polat.
The results are planned to be published in a medical journal.
IPD-Sharing-Zeitrahmen
IPD-Sharing-Zugriffskriterien
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .